SLQT · SelectQuote, Inc.
Market Cap
$70.63M
Shares
176.57M
Volume · Oct 5
406.72K
Avg daily vol (3M)
1.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.41
Open$0.43
Day$0.41–0.44
52W close$0.40–2.13
Avg vol 30d1.3M
Short int1.7M · 0.9% float · 2.1d
Short vol48%
Last earningsAug 25, 2026
DataMay 2020–Oct 2026
Filing10-K · Aug 25
Up next
Next earnings call
Nov 23, 2026
Est · unconfirmed
· in 7 wks
filed Aug 25, 2026
call held Aug 25, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.62B
Trailing 12 months
Net income (TTM)
$62.19M
Trailing 12 months
Revenue growth YoY
-6.8%
Year over year
Operating margin
4.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
39.1%
TTM · current market cap
Return on invested capital
8.5%
Trailing 12 months
Net cash
−$354.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
-80.1%
Trailing year
Short interest
0.9%
Latest settlement · 2.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−31%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−41%
trailing
YTD return
−71%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.94% of float · ▼ -26.0% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
155 holders — mid 3-yr range
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
EPS growth
−700%
Y/Y
Free cash flow
$27.6M
Balance sheet
$354.1M
net debt
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 25, 2026
Consolidated revenue
· 2027
$1.35B – $1.45B
prior FY $1.62B
midpoint −13.5% Y/Y
Adjusted EBITDA
· 2027
Non-GAAP
$90M – $115M
Operating cash flow
· 2027
at least $60M
Guided vs delivered
· last 4 settled
Revenue
Fiscal Year 2024
guided $1.25B – $1.3B
$1.32B
Beat +3.7%
Revenue
Fiscal Year 2023
guided $950M – $970M
$1B
Beat +4.5%
Revenue
2022
guided $810M – $850M
$764.05M
Miss −7.9%
Consolidated revenue
full fiscal year
guided $920M – $940M
$929.98M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−31%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.94% of float · ▼ -26.0% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
155 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 1%
Range high $2
vs 200-day avg -54%
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $109.1M | fiscal year 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) $62.19M
+$14.86M Share-based compensation expense
+$2.11M Transaction costs
+$17.49M Depreciation and amortization
+$0K Loss on disposal of property, equipment, and software, net
+$1M Impairment of equity-method investment
+$0K Impairment of long-lived asset
+$8.66M Loss on extinguishment of debt
-$55.8M Change in fair value of warrants
+$44.53M Interest expense, net
+$14.1M Income tax expense
= Adjusted EBITDA $109.13M
|
|||
| Adjusted EBITDA per MA/MS policy non-GAAP | $305 | Twelve Months Ended June 30, 2026 | — |
| Adjusted Segment EBITDA non-GAAP | $200.52M | Year Ended June 30, 2026 filing | -6.2% |
|
|
|||
| All other submitted policies | 90,253 | fiscal 2026 filing | — |
| Approved Medicare Advantage policies | 72,180 | Fourth Quarter Fiscal Year 2026 | — |
| Approved policies - All other | 71,298 | Year Ended June 30, 2026 | — |
| Approved policies - Medicare Advantage | 567,526 | Year Ended June 30, 2026 | — |
| Approved policies - Total | 638,824 | Year Ended June 30, 2026 | — |
| Final Expense Premiums | $109.93M | Year Ended June 30, 2026 | — |
| Healthcare Services Adjusted EBITDA Margin non-GAAP | 3% | Year Ended June 30, 2026 | — |
| Lifetime value of commissions per approved policy - All other | $122 | Year Ended June 30, 2026 | — |
| LTV per Approved Policy - Medicare Advantage | $873 | fiscal 2026 filing | — |
| MA and MS approved policies | 569,698 | Twelve Months Ended June 30, 2026 | — |
| MA and MS commission per MA / MS policy | $875 | Twelve Months Ended June 30, 2026 | — |
| Medicare Advantage submitted policies | 622,939 | fiscal 2026 filing | — |
| Other commission per MA/MS policy | $10 | Twelve Months Ended June 30, 2026 | — |
| Other revenue per MA/MS policy | $151 | Twelve Months Ended June 30, 2026 | — |
| Pharmacy revenue per MA/MS policy | $1,458 | Twelve Months Ended June 30, 2026 | — |
| Prescriptions Per Day | 32,215 | Year Ended June 30, 2026 | — |
| SelectRx members | 109,039 | fourth quarter of fiscal year 2026 | — |
| Submitted policies - All other | 90,253 | Year Ended June 30, 2026 | — |
| Submitted policies - Medicare Advantage | 622,939 | Year Ended June 30, 2026 | — |
| Submitted policies - Total | 713,192 | Year Ended June 30, 2026 | — |
| Term Premiums | $75.23M | Year Ended June 30, 2026 | — |
| Total Life Premiums | $185.16M | Year Ended June 30, 2026 | — |
| Total operating expenses per MA / MS policy | -$2,189 | Twelve Months Ended June 30, 2026 | — |
| Total Premiums | $185.16M | fiscal 2026 filing | — |
| Total revenue per MA / MS policy | $2,494 | Twelve Months Ended June 30, 2026 | — |
| Total SelectRx Members | 109,039 | fiscal 2026 filing | — |
| Total submitted policies | 713,192 | fiscal 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance Brokers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLQT
this stock
SelectQuote, Inc.
|
$70.63M | -70.9% | +6.0% | — | 0.9% |
|
MRSH
Marsh & Mclennan Companies, Inc.
|
$81.66B | -8.3% | +10.3% | 20.9 | 1.2% |
|
AJG
Arthur J. Gallagher & Co.
|
$58.90B | -12.6% | +10.1% | 38.1 | 2.5% |
|
AON
Aon plc
|
$58.11B | -23.6% | +7.7% | 15.1 | 1.7% |
|
WTW
Willis Towers Watson PLC
|
$27.30B | -12.2% | -2.2% | 18.2 | 2.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLQT | +2.7% | -24.4% | -40.6% | +1.5% | -70.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +2.9% | -23.9% | -52.8% | +0.5% | -83.7% |